Share Price and Basic Stock Data
Last Updated: December 13, 2025, 8:37 am
| PEG Ratio | 0.00 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Omaxe Ltd operates in the construction, contracting, and engineering sector, which has recently been under considerable pressure. The company reported a market capitalization of ₹1,168 Cr, with its share price at ₹63.9. The revenue trajectory illustrates a rollercoaster ride, with sales fluctuating significantly. For instance, sales peaked at ₹599 Cr in December 2023, only to fall to ₹289 Cr by December 2024. This inconsistency raises questions about demand stability and project execution. Notably, the trailing twelve months (TTM) revenue stands at ₹1,502 Cr, which suggests a recovery from prior lows but still reflects a challenging environment compared to historical figures. The recent decline in sales during the Jun 2025 quarter to ₹282 Cr indicates that Omaxe is grappling with maintaining momentum amidst a competitive and often volatile market.
Profitability and Efficiency Metrics
Profitability metrics for Omaxe Ltd paint a concerning picture. The company has reported negative net profits consistently, with a staggering loss of ₹724 Cr in the latest financial year. Operating profit margins (OPM) have remained deeply in the red, with figures reflecting -60% as of Jun 2025. This situation seems unsustainable, especially when coupled with a return on equity (ROE) of 506%—a figure that, while impressive, is a result of a drastically diminished equity base due to accumulated losses. The interest coverage ratio (ICR) stands at a worrying -2.72x, indicating that the company is struggling to meet its interest obligations. This financial strain raises significant concerns regarding Omaxe’s operational efficiency and overall viability in a sector that typically demands robust margins and effective cost management.
Balance Sheet Strength and Financial Ratios
The balance sheet of Omaxe Ltd reveals a mix of strengths and weaknesses. On the one hand, the company’s borrowings have reached ₹1,419 Cr, reflecting a heavy reliance on debt, which is concerning given the declining reserves that now stand at -₹740 Cr. Notably, the price-to-book value (P/BV) ratio is a staggering -6.96x, highlighting the company’s eroded equity position. The current ratio of 0.95 suggests that while Omaxe can cover its short-term liabilities, its margin of safety is slim. Conversely, the cash conversion cycle (CCC) has improved to 73 days, indicating some operational efficiency in managing receivables and payables. However, with total liabilities reaching ₹15,728 Cr, the company’s leverage poses a significant risk, especially if operational challenges persist.
Shareholding Pattern and Investor Confidence
The shareholding structure of Omaxe Ltd displays a solid promoter holding of 74.14%, which can provide a sense of stability in governance. However, the decline in foreign institutional investment (FIIs) from 9.15% in December 2022 to 6.06% in September 2025 may signal waning confidence among international investors. Domestic institutional investors (DIIs) have also reduced their stake from 2.69% to 1.56% over the same period, reflecting a cautious approach in light of the company’s financial challenges. The public shareholding has increased slightly to 18.23%, indicating some retail interest, yet the overall sentiment appears cautious. With over 49,331 shareholders, the dilution of investor confidence could pose challenges for Omaxe in raising capital or stabilizing its stock price in the future.
Outlook, Risks, and Final Insight
Looking ahead, Omaxe Ltd faces a myriad of risks that could influence its market position. The ongoing challenges in achieving consistent revenue growth and profitability remain paramount. Investors should be particularly wary of the company’s heavy debt load, which could become a significant burden if operational performance does not improve. Additionally, the fluctuating interest coverage ratio suggests potential liquidity issues that could hinder financial flexibility. On the positive side, if Omaxe can successfully navigate its operational challenges and stabilize its revenue streams, it may present a turnaround opportunity. However, any investment should be approached with caution, weighing the inherent risks against the potential for recovery in a sector that is gradually evolving. For retail investors, a thorough assessment of the company’s strategic plans and execution capabilities will be crucial in determining whether Omaxe represents a viable long-term investment.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Modern Engineering and Projects Ltd | 53.4 Cr. | 34.6 | 49.9/22.5 | 5.08 | 39.4 | 0.00 % | 20.5 % | 25.9 % | 10.0 |
| Modis Navnirman Ltd | 677 Cr. | 346 | 409/220 | 82.6 | 46.5 | 0.00 % | 12.9 % | 9.88 % | 10.0 |
| Modulex Construction Technologies Ltd | 143 Cr. | 20.7 | 35.7/18.0 | 44.7 | 0.00 % | 2.51 % | 1.54 % | 10.0 | |
| MPDL Ltd | 34.0 Cr. | 45.9 | 92.7/38.0 | 127 | 0.00 % | 2.87 % | 4.16 % | 10.0 | |
| IITL Projects Ltd | 29.3 Cr. | 58.7 | 77.9/47.1 | 2.12 | 0.00 % | 16.6 % | % | 10.0 | |
| Industry Average | 17,241.90 Cr | 247.30 | 77.47 | 138.42 | 0.16% | 16.68% | 21.32% | 21.41 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 121 | 119 | 244 | 289 | 213 | 266 | 599 | 536 | 342 | 389 | 289 | 541 | 282 |
| Expenses | 145 | 187 | 346 | 399 | 306 | 333 | 637 | 682 | 493 | 613 | 416 | 647 | 452 |
| Operating Profit | -23 | -68 | -102 | -109 | -93 | -67 | -37 | -146 | -151 | -224 | -127 | -106 | -170 |
| OPM % | -19% | -57% | -42% | -38% | -43% | -25% | -6% | -27% | -44% | -58% | -44% | -20% | -60% |
| Other Income | 3 | 3 | 10 | 9 | 7 | 4 | 3 | 7 | 44 | 9 | 11 | 12 | 16 |
| Interest | 29 | 31 | 27 | 26 | 31 | 29 | 32 | 38 | 42 | 45 | 57 | 51 | 67 |
| Depreciation | 17 | 16 | 16 | 16 | 16 | 10 | 15 | 14 | 7 | 7 | 10 | 12 | 7 |
| Profit before tax | -66 | -112 | -136 | -143 | -132 | -103 | -82 | -191 | -157 | -267 | -183 | -157 | -228 |
| Tax % | -24% | -22% | -20% | -27% | -19% | -18% | -12% | -25% | -6% | -10% | -18% | -5% | -19% |
| Net Profit | -50 | -87 | -109 | -104 | -106 | -84 | -72 | -144 | -147 | -239 | -150 | -149 | -186 |
| EPS in Rs | -2.68 | -4.78 | -5.79 | -5.77 | -5.81 | -4.61 | -3.66 | -7.93 | -8.06 | -13.10 | -8.23 | -8.11 | -10.16 |
Last Updated: August 20, 2025, 6:00 am
Below is a detailed analysis of the quarterly data for Omaxe Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 282.00 Cr.. The value appears to be declining and may need further review. It has decreased from 541.00 Cr. (Mar 2025) to 282.00 Cr., marking a decrease of 259.00 Cr..
- For Expenses, as of Jun 2025, the value is 452.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 647.00 Cr. (Mar 2025) to 452.00 Cr., marking a decrease of 195.00 Cr..
- For Operating Profit, as of Jun 2025, the value is -170.00 Cr.. The value appears to be declining and may need further review. It has decreased from -106.00 Cr. (Mar 2025) to -170.00 Cr., marking a decrease of 64.00 Cr..
- For OPM %, as of Jun 2025, the value is -60.00%. The value appears to be declining and may need further review. It has decreased from -20.00% (Mar 2025) to -60.00%, marking a decrease of 40.00%.
- For Other Income, as of Jun 2025, the value is 16.00 Cr.. The value appears strong and on an upward trend. It has increased from 12.00 Cr. (Mar 2025) to 16.00 Cr., marking an increase of 4.00 Cr..
- For Interest, as of Jun 2025, the value is 67.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 51.00 Cr. (Mar 2025) to 67.00 Cr., marking an increase of 16.00 Cr..
- For Depreciation, as of Jun 2025, the value is 7.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 12.00 Cr. (Mar 2025) to 7.00 Cr., marking a decrease of 5.00 Cr..
- For Profit before tax, as of Jun 2025, the value is -228.00 Cr.. The value appears to be declining and may need further review. It has decreased from -157.00 Cr. (Mar 2025) to -228.00 Cr., marking a decrease of 71.00 Cr..
- For Tax %, as of Jun 2025, the value is -19.00%. The value appears to be improving (decreasing) as expected. It has decreased from -5.00% (Mar 2025) to -19.00%, marking a decrease of 14.00%.
- For Net Profit, as of Jun 2025, the value is -186.00 Cr.. The value appears to be declining and may need further review. It has decreased from -149.00 Cr. (Mar 2025) to -186.00 Cr., marking a decrease of 37.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is -10.16. The value appears to be declining and may need further review. It has decreased from -8.11 (Mar 2025) to -10.16, marking a decrease of 2.05.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: August 23, 2025, 2:21 pm
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,605 | 1,414 | 1,386 | 1,627 | 1,839 | 1,167 | 1,121 | 476 | 618 | 773 | 1,614 | 1,561 | 1,502 |
| Expenses | 1,378 | 1,180 | 1,144 | 1,343 | 1,579 | 1,038 | 924 | 594 | 665 | 1,077 | 1,958 | 2,169 | 2,128 |
| Operating Profit | 226 | 234 | 242 | 284 | 260 | 128 | 198 | -119 | -47 | -303 | -343 | -608 | -626 |
| OPM % | 14% | 17% | 17% | 17% | 14% | 11% | 18% | -25% | -8% | -39% | -21% | -39% | -42% |
| Other Income | 30 | 34 | 54 | 59 | 59 | 34 | 28 | 39 | 20 | 25 | 21 | 76 | 48 |
| Interest | 131 | 144 | 147 | 155 | 169 | 74 | 108 | 161 | 121 | 113 | 130 | 195 | 220 |
| Depreciation | 10 | 14 | 10 | 9 | 9 | 9 | 73 | 63 | 47 | 65 | 54 | 37 | 37 |
| Profit before tax | 116 | 110 | 139 | 179 | 141 | 79 | 44 | -305 | -194 | -457 | -507 | -764 | -835 |
| Tax % | 32% | 46% | 45% | 41% | 39% | 38% | 319% | -23% | -17% | -23% | -20% | -10% | |
| Net Profit | 79 | 60 | 77 | 105 | 85 | 49 | -97 | -235 | -162 | -351 | -406 | -685 | -724 |
| EPS in Rs | 4.29 | 3.28 | 4.20 | 5.58 | 4.59 | 2.68 | -5.32 | -12.86 | -8.72 | -19.02 | -22.01 | -37.51 | -39.60 |
| Dividend Payout % | 12% | 15% | 17% | 13% | 15% | 26% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | -24.05% | 28.33% | 36.36% | -19.05% | -42.35% | -297.96% | -142.27% | 31.06% | -116.67% | -15.67% | -68.72% |
| Change in YoY Net Profit Growth (%) | 0.00% | 52.38% | 8.03% | -55.41% | -23.31% | -255.61% | 155.69% | 173.33% | -147.73% | 101.00% | -53.05% |
Omaxe Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 1% |
| 5 Years: | 7% |
| 3 Years: | 36% |
| TTM: | -14% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| TTM: | -63% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | -4% |
| 5 Years: | 5% |
| 3 Years: | -5% |
| 1 Year: | -30% |
| Return on Equity | |
|---|---|
| 10 Years: | -11% |
| 5 Years: | -39% |
| 3 Years: | -76% |
| Last Year: | -498% |
Last Updated: September 5, 2025, 11:55 am
Balance Sheet
Last Updated: December 4, 2025, 1:44 am
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 | 183 |
| Reserves | 1,746 | 1,794 | 1,848 | 1,936 | 2,014 | 1,558 | 1,456 | 1,222 | 1,062 | 715 | 298 | -388 | -740 |
| Borrowings | 1,299 | 1,346 | 1,328 | 1,503 | 1,802 | 1,856 | 1,672 | 1,530 | 1,128 | 1,107 | 796 | 796 | 1,419 |
| Other Liabilities | 3,225 | 3,585 | 4,353 | 4,704 | 4,129 | 7,163 | 7,239 | 8,108 | 9,545 | 11,555 | 12,546 | 14,300 | 14,866 |
| Total Liabilities | 6,453 | 6,908 | 7,712 | 8,326 | 8,128 | 10,760 | 10,549 | 11,042 | 11,918 | 13,560 | 13,822 | 14,891 | 15,728 |
| Fixed Assets | 131 | 118 | 600 | 604 | 604 | 599 | 747 | 671 | 627 | 582 | 565 | 606 | 595 |
| CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments | 16 | 20 | 22 | 12 | 12 | 12 | 12 | 12 | 13 | 14 | 29 | 21 | 20 |
| Other Assets | 6,306 | 6,769 | 7,091 | 7,710 | 7,512 | 10,149 | 9,789 | 10,359 | 11,278 | 12,964 | 13,228 | 14,264 | 15,112 |
| Total Assets | 6,453 | 6,908 | 7,712 | 8,326 | 8,128 | 10,760 | 10,549 | 11,042 | 11,918 | 13,560 | 13,822 | 14,891 | 15,728 |
Below is a detailed analysis of the balance sheet data for Omaxe Ltd based on the most recent figures (Sep 2025) and their trends compared to the previous period:
- For Equity Capital, as of Sep 2025, the value is 183.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 183.00 Cr..
- For Reserves, as of Sep 2025, the value is -740.00 Cr.. The value appears to be worsening (becoming more negative). It has deteriorated from -388.00 Cr. (Mar 2025) to -740.00 Cr., marking a decline of 352.00 Cr..
- For Borrowings, as of Sep 2025, the value is 1,419.00 Cr.. The value appears to be increasing, which may not be favorable. However, Reserves are negative, which is a major warning sign. It has increased from 796.00 Cr. (Mar 2025) to 1,419.00 Cr., marking an increase of 623.00 Cr..
- For Other Liabilities, as of Sep 2025, the value is 14,866.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,300.00 Cr. (Mar 2025) to 14,866.00 Cr., marking an increase of 566.00 Cr..
- For Total Liabilities, as of Sep 2025, the value is 15,728.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 14,891.00 Cr. (Mar 2025) to 15,728.00 Cr., marking an increase of 837.00 Cr..
- For Fixed Assets, as of Sep 2025, the value is 595.00 Cr.. The value appears to be declining and may need further review. It has decreased from 606.00 Cr. (Mar 2025) to 595.00 Cr., marking a decrease of 11.00 Cr..
- For CWIP, as of Sep 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Investments, as of Sep 2025, the value is 20.00 Cr.. The value appears to be declining and may need further review. It has decreased from 21.00 Cr. (Mar 2025) to 20.00 Cr., marking a decrease of 1.00 Cr..
- For Other Assets, as of Sep 2025, the value is 15,112.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,264.00 Cr. (Mar 2025) to 15,112.00 Cr., marking an increase of 848.00 Cr..
- For Total Assets, as of Sep 2025, the value is 15,728.00 Cr.. The value appears strong and on an upward trend. It has increased from 14,891.00 Cr. (Mar 2025) to 15,728.00 Cr., marking an increase of 837.00 Cr..
However, the Borrowings (1,419.00 Cr.) are higher than the Reserves (-740.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 225.00 | 233.00 | 241.00 | 283.00 | 259.00 | 127.00 | 197.00 | -120.00 | -48.00 | -304.00 | -1,139.00 | -1,404.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 197 | 199 | 208 | 235 | 158 | 110 | 111 | 298 | 227 | 182 | 81 | 73 |
| Inventory Days | 16,214 | |||||||||||
| Days Payable | 1,755 | |||||||||||
| Cash Conversion Cycle | 197 | 199 | 208 | 235 | 158 | 110 | 111 | 298 | 227 | 182 | 14,539 | 73 |
| Working Capital Days | 470 | 601 | 570 | 547 | 461 | 532 | 508 | 911 | 424 | 156 | -62 | -333 |
| ROCE % | 8% | 8% | 9% | 10% | 8% | 4% | 5% | -5% | -3% | -16% | -23% | -61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| Diluted EPS (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| Cash EPS (Rs.) | -35.45 | -19.24 | -15.62 | -6.29 | -9.39 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | -11.22 | 14.42 | 37.44 | 56.57 | 65.43 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | -11.22 | 14.42 | 37.44 | 56.57 | 65.43 |
| Revenue From Operations / Share (Rs.) | 85.35 | 88.26 | 42.28 | 33.78 | 26.01 |
| PBDIT / Share (Rs.) | -29.07 | -17.64 | -15.23 | -1.46 | -4.36 |
| PBIT / Share (Rs.) | -31.08 | -20.61 | -18.81 | -4.01 | -7.83 |
| PBT / Share (Rs.) | -41.76 | -27.74 | -24.97 | -10.63 | -16.66 |
| Net Profit / Share (Rs.) | -37.46 | -22.20 | -19.20 | -8.84 | -12.86 |
| NP After MI And SOA / Share (Rs.) | -37.51 | -22.01 | -19.02 | -8.72 | -12.86 |
| PBDIT Margin (%) | -34.06 | -19.98 | -36.02 | -4.32 | -16.77 |
| PBIT Margin (%) | -36.41 | -23.35 | -44.47 | -11.86 | -30.10 |
| PBT Margin (%) | -48.92 | -31.42 | -59.06 | -31.46 | -64.04 |
| Net Profit Margin (%) | -43.89 | -25.15 | -45.39 | -26.16 | -49.44 |
| NP After MI And SOA Margin (%) | -43.94 | -24.93 | -44.98 | -25.82 | -49.43 |
| Return on Networth / Equity (%) | 0.00 | -157.76 | -51.69 | -15.64 | -19.93 |
| Return on Capital Employeed (%) | -61.52 | -23.15 | -16.47 | -3.32 | -5.47 |
| Return On Assets (%) | -4.61 | -2.91 | -2.56 | -1.33 | -2.12 |
| Long Term Debt / Equity (X) | -2.43 | 1.95 | 0.98 | 0.42 | 0.67 |
| Total Debt / Equity (X) | -3.62 | 2.86 | 1.37 | 0.90 | 0.80 |
| Asset Turnover Ratio (%) | 0.10 | 0.11 | 0.06 | 0.04 | 0.03 |
| Current Ratio (X) | 0.95 | 1.02 | 1.07 | 1.10 | 1.17 |
| Quick Ratio (X) | 0.16 | 0.15 | 0.16 | 0.15 | 0.15 |
| Inventory Turnover Ratio (X) | 0.19 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (X) | -2.72 | -2.48 | -2.47 | -0.22 | -0.49 |
| Interest Coverage Ratio (Post Tax) (X) | -2.51 | -2.12 | -2.11 | -0.33 | -0.45 |
| Enterprise Value (Cr.) | 1437.16 | 1855.26 | 1453.09 | 2188.62 | 2001.51 |
| EV / Net Operating Revenue (X) | 0.92 | 1.15 | 1.88 | 3.54 | 4.21 |
| EV / EBITDA (X) | -2.70 | -5.75 | -5.22 | -81.94 | -25.08 |
| MarketCap / Net Operating Revenue (X) | 0.91 | 1.03 | 1.18 | 2.37 | 2.59 |
| Price / BV (X) | -6.96 | 6.50 | 1.36 | 1.44 | 1.04 |
| Price / Net Operating Revenue (X) | 0.91 | 1.03 | 1.18 | 2.37 | 2.59 |
| EarningsYield | -0.48 | -0.24 | -0.38 | -0.10 | -0.19 |
After reviewing the key financial ratios for Omaxe Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For Diluted EPS (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 5. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For Cash EPS (Rs.), as of Mar 25, the value is -35.45. This value is below the healthy minimum of 3. It has decreased from -19.24 (Mar 24) to -35.45, marking a decrease of 16.21.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -11.22. It has decreased from 14.42 (Mar 24) to -11.22, marking a decrease of 25.64.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is -11.22. It has decreased from 14.42 (Mar 24) to -11.22, marking a decrease of 25.64.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 85.35. It has decreased from 88.26 (Mar 24) to 85.35, marking a decrease of 2.91.
- For PBDIT / Share (Rs.), as of Mar 25, the value is -29.07. This value is below the healthy minimum of 2. It has decreased from -17.64 (Mar 24) to -29.07, marking a decrease of 11.43.
- For PBIT / Share (Rs.), as of Mar 25, the value is -31.08. This value is below the healthy minimum of 0. It has decreased from -20.61 (Mar 24) to -31.08, marking a decrease of 10.47.
- For PBT / Share (Rs.), as of Mar 25, the value is -41.76. This value is below the healthy minimum of 0. It has decreased from -27.74 (Mar 24) to -41.76, marking a decrease of 14.02.
- For Net Profit / Share (Rs.), as of Mar 25, the value is -37.46. This value is below the healthy minimum of 2. It has decreased from -22.20 (Mar 24) to -37.46, marking a decrease of 15.26.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is -37.51. This value is below the healthy minimum of 2. It has decreased from -22.01 (Mar 24) to -37.51, marking a decrease of 15.50.
- For PBDIT Margin (%), as of Mar 25, the value is -34.06. This value is below the healthy minimum of 10. It has decreased from -19.98 (Mar 24) to -34.06, marking a decrease of 14.08.
- For PBIT Margin (%), as of Mar 25, the value is -36.41. This value is below the healthy minimum of 10. It has decreased from -23.35 (Mar 24) to -36.41, marking a decrease of 13.06.
- For PBT Margin (%), as of Mar 25, the value is -48.92. This value is below the healthy minimum of 10. It has decreased from -31.42 (Mar 24) to -48.92, marking a decrease of 17.50.
- For Net Profit Margin (%), as of Mar 25, the value is -43.89. This value is below the healthy minimum of 5. It has decreased from -25.15 (Mar 24) to -43.89, marking a decrease of 18.74.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is -43.94. This value is below the healthy minimum of 8. It has decreased from -24.93 (Mar 24) to -43.94, marking a decrease of 19.01.
- For Return on Networth / Equity (%), as of Mar 25, the value is 0.00. This value is below the healthy minimum of 15. It has increased from -157.76 (Mar 24) to 0.00, marking an increase of 157.76.
- For Return on Capital Employeed (%), as of Mar 25, the value is -61.52. This value is below the healthy minimum of 10. It has decreased from -23.15 (Mar 24) to -61.52, marking a decrease of 38.37.
- For Return On Assets (%), as of Mar 25, the value is -4.61. This value is below the healthy minimum of 5. It has decreased from -2.91 (Mar 24) to -4.61, marking a decrease of 1.70.
- For Long Term Debt / Equity (X), as of Mar 25, the value is -2.43. This value is below the healthy minimum of 0.2. It has decreased from 1.95 (Mar 24) to -2.43, marking a decrease of 4.38.
- For Total Debt / Equity (X), as of Mar 25, the value is -3.62. This value is within the healthy range. It has decreased from 2.86 (Mar 24) to -3.62, marking a decrease of 6.48.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.10. It has decreased from 0.11 (Mar 24) to 0.10, marking a decrease of 0.01.
- For Current Ratio (X), as of Mar 25, the value is 0.95. This value is below the healthy minimum of 1.5. It has decreased from 1.02 (Mar 24) to 0.95, marking a decrease of 0.07.
- For Quick Ratio (X), as of Mar 25, the value is 0.16. This value is below the healthy minimum of 1. It has increased from 0.15 (Mar 24) to 0.16, marking an increase of 0.01.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.19. This value is below the healthy minimum of 4. It has increased from 0.00 (Mar 24) to 0.19, marking an increase of 0.19.
- For Interest Coverage Ratio (X), as of Mar 25, the value is -2.72. This value is below the healthy minimum of 3. It has decreased from -2.48 (Mar 24) to -2.72, marking a decrease of 0.24.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is -2.51. This value is below the healthy minimum of 3. It has decreased from -2.12 (Mar 24) to -2.51, marking a decrease of 0.39.
- For Enterprise Value (Cr.), as of Mar 25, the value is 1,437.16. It has decreased from 1,855.26 (Mar 24) to 1,437.16, marking a decrease of 418.10.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 0.92. This value is below the healthy minimum of 1. It has decreased from 1.15 (Mar 24) to 0.92, marking a decrease of 0.23.
- For EV / EBITDA (X), as of Mar 25, the value is -2.70. This value is below the healthy minimum of 5. It has increased from -5.75 (Mar 24) to -2.70, marking an increase of 3.05.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
- For Price / BV (X), as of Mar 25, the value is -6.96. This value is below the healthy minimum of 1. It has decreased from 6.50 (Mar 24) to -6.96, marking a decrease of 13.46.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 0.91. This value is below the healthy minimum of 1. It has decreased from 1.03 (Mar 24) to 0.91, marking a decrease of 0.12.
- For EarningsYield, as of Mar 25, the value is -0.48. This value is below the healthy minimum of 5. It has decreased from -0.24 (Mar 24) to -0.48, marking a decrease of 0.24.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Omaxe Ltd:
- Net Profit Margin: -43.89%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: -61.52% (Industry Average ROCE: 16.68%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 0% (Industry Average ROE: 21.32%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): -2.51
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.16
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 0 (Industry average Stock P/E: 77.47)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: -3.62
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: -43.89%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Construction, Contracting & Engineering | Shop No. 19-B, First Floor, Gurgaon Haryana 122001 | secretarial_1@omaxe.com http://www.omaxe.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Rohtas Goel | Chairman & Non-Exe.Director |
| Mr. Mohit Goel | Managing Director |
| Mr. Vinit Goyal | Whole Time Director |
| Ms. Nishal Jain | Non Exe. Women Independent Director |
| Mr. Shridhar Rao | Ind. Non-Executive Director |
| Mr. Aroon Kumar Aggarwal | Ind. Non-Executive Director |
| Ms. Binitha Manohar Dalal | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Omaxe Ltd?
Omaxe Ltd's intrinsic value (as of 13 December 2025) is 1882.81 which is 2796.63% higher the current market price of 65.00, indicating undervalued. Calculated using the PE ratio method, this valuation considers the company's 1,189 Cr. market cap, FY2025-2026 high/low of 127/62.5, reserves of ₹-740 Cr, and liabilities of 15,728 Cr.
What is the Market Cap of Omaxe Ltd?
The Market Cap of Omaxe Ltd is 1,189 Cr..
What is the current Stock Price of Omaxe Ltd as on 13 December 2025?
The current stock price of Omaxe Ltd as on 13 December 2025 is 65.0.
What is the High / Low of Omaxe Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Omaxe Ltd stocks is 127/62.5.
What is the Stock P/E of Omaxe Ltd?
The Stock P/E of Omaxe Ltd is .
What is the Book Value of Omaxe Ltd?
The Book Value of Omaxe Ltd is 30.4.
What is the Dividend Yield of Omaxe Ltd?
The Dividend Yield of Omaxe Ltd is 0.00 %.
What is the ROCE of Omaxe Ltd?
The ROCE of Omaxe Ltd is 61.4 %.
What is the ROE of Omaxe Ltd?
The ROE of Omaxe Ltd is 506 %.
What is the Face Value of Omaxe Ltd?
The Face Value of Omaxe Ltd is 10.0.